Weitai Medical-B (02235): Continuous Glucose Monitoring System Approved Overseas

Zhitong Finance App News, Weitai Medical-B (02235) announced that our LinX continuous glucose monitoring system has recently been approved for marketing in South Korea and is suitable for continuous dynamic blood sugar monitoring in adults.

As a key market in East Asia, Korea has perfect medical insurance coverage, strong patients' ability to pay, and broad market development prospects. According to the International Diabetes Federation (IDF)'s “2025 Global Diabetes Map” data, in 2024, South Korea had about 5 million diabetics aged 20-79, with an adult prevalence rate of 9.6%; the total annual medical expenses related to diabetes in South Korea were about 11.63 billion US dollars, and the average annual medical expenses related to a single diabetic reached 2,312.1 US dollars. The per capita medical investment was at the top of the Asian economy.

The company's LinX continuous glucose monitoring system was approved for listing in Korea, which will greatly improve the company's entry layout in the East Asian market, strengthen the Group's channel competitiveness in mature Asian markets, and lay a solid foundation for large-scale expansion of international business and overseas revenue growth. In the future, the company will continue to focus on the global development of diabetes monitoring, treatment and management methods, and continue to promote technological and product innovation in related fields.